The Canberra Family Study: A prospective study of new parents following the birth of their child to improve maternity service and family healthcare outcomes.

开始日期2024-08-01

申办/合作机构

Canberra Hospital Foundation

[+1]

ACTRN12624000573550 / Not yet recruitingN/AIIT

Inspire Beyond ICU – An audit of usual care physiotherapy in Australian and New Zealand ICU’s for adults who are mechanically ventilated 5 days or longer

开始日期2024-06-01

申办/合作机构

Canberra Hospital Foundation

[+1]

ACTRN12623001232628 / Not yet recruitingN/AIIT

Laryngoscope-Bougie Guided i-gel Insertion in Difficult Airways: A Feasibility Trial

开始日期2024-01-01

申办/合作机构

Canberra Hospital Foundation

100 项与 Canberra Hospital Foundation 相关的临床结果

登录后查看更多信息

0 项与 Canberra Hospital Foundation 相关的专利（医药）

登录后查看更多信息

1,808

项与 Canberra Hospital Foundation 相关的文献（医药）

2024-06-01·Seminars in Arthritis and Rheumatism

Strategies to promote implementation of core outcomes for medication adherence trials in rheumatology: A report from the OMERACT-Adherence Group

Article

作者: Bekker, Charlotte ; Hoens, Alison M ; Carmona, Loreto ; de Wit, Maarten ; Tymms, Kathleen ; Kelly, Ayano ; Nielsen, Sabrina Mai ; Shea, Beverley J ; Tugwell, Peter ; Campbell, Willemina ; Toupin-April, Karine ; March, Lyn ; Kordkheili, Aria Mohammadi ; Voshaar, Marieke

OBJECTIVESTo identify barriers, facilitators, and strategies for future implementation of the OMERACT-Adherence Core Outcome Set (COS) in medication adherence trials for rheumatic conditions.METHODSPreliminary Delphi survey findings were discussed at OMERACT 2023, utilising the Consolidated Framework for Implementation Research 2 to identify implementation barriers, facilitators, and solutions.RESULTSImplementation strategies included simplifying the COS definitions, making it adaptabile for clinical practice and drug trials, adherence trial training workshops, and collaborating with key stakeholders such as payers and other COS developers.CONCLUSIONOngoing collaboration with individuals and organisations within and beyond rheumatology ensures broader applicability of OMERACT-Adherence COS.

2023-12-07·Blood

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

Article

作者: Yuen, Sam ; Wall, Meaghan ; Kennedy, Glen A ; Iland, Harry J ; Schwarer, Anthony P ; He, Simon ; Murphy, Nick ; Leadbetter, Joanna ; Latimer, Maya ; Verner, Emma ; Levis, Mark J ; Roberts, Andrew W ; Tiley, Campbell ; Wei, Andrew H ; Hahn, Uwe ; Ong, Doen Ming ; Bajel, Ashish ; Marlton, Paula ; Ramanathan, Sundra ; Cull, Gavin ; Morris, Kirk ; Tiong, Ing Soo ; Anstee, Natasha S ; Rowley, Leesa ; D'Rozario, James ; Reynolds, John ; Rawling, Tristan ; Enjeti, Anoop K ; Loo, Sun ; Taper, John ; Hiwase, Devendra K ; Fong, Chun Yew ; Bilmon, Ian A ; Ting, Stephen B ; Murray, Michael ; Seymour, John F

AbstractSorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising outcomes have been reported for sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) randomized 102 patients (aged 18-65 years) 2:1 to sorafenib vs placebo (days 4-10) combined with intensive induction: idarubicin 12 mg/m2 on days 1 to 3 plus either cytarabine 1.5 g/m2 twice daily on days 1, 3, 5, and 7 (18-55 years) or 100 mg/m2 on days 1 to 7 (56-65 years), followed by consolidation and maintenance therapy for 12 months (post-HCT excluded) in newly diagnosed patients with FLT3-ITD AML. Four patients were excluded in a modified intention-to-treat final analysis (3 not commencing therapy and 1 was FLT3-ITD negative). Rates of complete remission (CR)/CR with incomplete hematologic recovery were high in both arms (sorafenib, 78%/9%; placebo, 70%/24%). With 49.1-months median follow-up, the primary end point of event-free survival (EFS) was not improved by sorafenib (2-year EFS 47.9% vs 45.4%; hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.51-1.51; P = .61). Two-year overall survival (OS) was 67% in the sorafenib arm and 58% in the placebo arm (HR, 0.76; 95% CI, 0.42-1.39). For patients who received HCT in first remission, the 2-year OS rates were 84% and 67% in the sorafenib and placebo arms, respectively (HR, 0.45; 95% CI, 0.18-1.12; P = .08). In exploratory analyses, FLT3-ITD measurable residual disease (MRD) negative status (<0.001%) after induction was associated with improved 2-year OS (83% vs 60%; HR, 0.4; 95% CI, 0.17-0.93; P = .028). In conclusion, routine use of pretransplant sorafenib plus chemotherapy in unselected patients with FLT3-ITD AML is not supported by this study.

2023-12-01·The Journal of Hand Surgery

Union and Complication Rates After Total Wrist Arthrodesis: A Systematic Review and Meta-Analysis

Article

作者: Perriman, Diana M ; Smith, Paul N ; Roberts, Chris J ; Booth, Joshua W ; Agius, Paul A ; Owen, David H

PURPOSETotal wrist arthrodesis (TWA) has been performed using various techniques. We aimed to provide pooled prevalence estimates of union and complications of TWA by technique. A secondary aim was to provide estimates of union and complication rates by treatment of the carpometacarpal joint (CMCJ) in TWA using plates. Given the widespread adoption of wrist arthrodesis plates (WAP), we hypothesized that these implants would result in higher union and lower complication rates. We also hypothesized that TWA with CMCJ arthrodesis would improve these outcomes.METHODSOnline databases including PubMed, Medline, Embase, and Cochrane were searched. Studies reporting union and/or complication rates of 10 or more TWA performed with a similar technique (analyzed as bone graft only, bone graft with minimal fixation, intramedullary, augmented intramedullary, plate, WAP, and other) were included. Studies with fewer than 10 TWA, studies reporting TWA where union or complications could not be analyzed separately, and studies without union and complication rates were excluded. Data extraction was performed independently by two English-speaking reviewers with a translator where required. Pooled prevalence estimates were made using a random-effects meta-analysis model and presented as a percent prevalence with 95% confidence and prediction intervals.RESULTSOne hundred and thirty-six studies with a total of 3,517 patients and 3,969 TWA were analyzed. No differences in union and complication prevalence were observed between TWA techniques and in TWA with different treatments of the CMCJ using plates and WAP.CONCLUSIONUsing meta-analysis, we found no difference in union and complication prevalence between TWA techniques and TWA with different treatments of the CMCJ with plates and WAP. It must be acknowledged that this research included low-quality studies with high heterogeneity, and confidence in the precision of the estimates is low.TYPE OF STUDY/LEVEL OF EVIDENCEPrognostic IV.

100 项与 Canberra Hospital Foundation 相关的药物交易

登录后查看更多信息

100 项与 Canberra Hospital Foundation 相关的转化医学

登录后查看更多信息